Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. Those figures were published after market hours Tuesday, so the Wednesday fallout was ugly, with the company's stock closing 21.8% lower.
In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000). On the bottom line, the biotech posted a loss of $90.9 million -- $3.50 per share -- compared to the year-ago deficit of $78.2 million. The company's tally of cash, cash equivalents , and liquid securities fell to $217.9 million from $305 million at the end of the preceding quarter.
Image source: Getty Images.
For further details see:
Why Esperion Therapeutics Plummeted Nearly 22% Today